Cell-based drug delivery.

Drug delivery has been greatly improved over the years by means of chemical and physical agents that increase bioavailability, improve pharmacokinetic and reduce toxicities. At the same time, cell based delivery systems have also been developed. These possesses a number of advantages including prolonged delivery times, targeting of drugs to specialized cell compartments and biocompatibility. Here we'll focus on erythrocyte-based drug delivery. These systems are especially efficient in releasing drugs in circulations for weeks, have a large capacity, can be easily processed and could accommodate traditional and biologic drugs. These carriers have also been used for delivering antigens and/or contrasting agents. Carrier erythrocytes have been evaluated in thousands of drug administration in humans proving safety and efficacy of the treatments. Erythrocyte-based delivery of new and conventional drugs is thus experiencing increasing interests in drug delivery and in managing complex pathologies especially when side effects could become serious issues.

[1]  L. McCormick,et al.  Transduced monocyte/macrophages targeted to murine skin by UV light , 2006, Experimental dermatology.

[2]  A. Gothoskar Resealed erythrocytes: A review , 2004 .

[3]  Freddie H Fu,et al.  Cartilage repair using bone morphogenetic protein 4 and muscle-derived stem cells. , 2006, Arthritis and rheumatism.

[4]  A. Palamara,et al.  Erythrocytes as carriers of reduced glutathione (GSH) in the treatment of retroviral infections. , 2003, The Journal of antimicrobial chemotherapy.

[5]  Deng-Fwu Hwang,et al.  In vitro cytotoxicitiy of silica nanoparticles at high concentrations strongly depends on the metabolic activity type of the cell line. , 2007, Environmental science & technology.

[6]  L. Chieco‐Bianchi,et al.  Gene therapy of ovarian cancer with IFN-α-producing fibroblasts: comparison of constitutive and inducible vectors , 2006, Gene Therapy.

[7]  A. Palamara,et al.  Inhibition of murine AIDS by reduced glutathione. , 1996, AIDS research and human retroviruses.

[8]  L Bigi,et al.  Erythrocyte‐mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease , 2001, Biotechnology and applied biochemistry.

[9]  M. Magnani,et al.  Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Magnani,et al.  Red Blood Cells as a Glucocorticoids Delivery System , 1997 .

[11]  Vladimir R Muzykantov,et al.  Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes , 2003, Nature Biotechnology.

[12]  N. K. Jain,et al.  Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro , 2007, Journal of drug targeting.

[13]  A. Aderem,et al.  Mechanisms of phagocytosis in macrophages. , 1999, Annual review of immunology.

[14]  S. Staprans,et al.  Administration of Fludarabine-Loaded Autologous Red Blood Cells in Simian Immunodeficiency Virus-Infected Sooty Mangabeys Depletes pSTAT-1-Expressing Macrophages and Delays the Rebound of Viremia after Suspension of Antiretroviral Therapy , 2006, Journal of Virology.

[15]  R. Freitas Pharmacytes: an ideal vehicle for targeted drug delivery. , 2006, Journal of nanoscience and nanotechnology.

[16]  M. Magnani,et al.  Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides , 2002, Gene Therapy.

[17]  H. Arima,et al.  Specific inhibition of nitric oxide production in macrophages by phosphorothioate antisense oligonucleotides. , 1997, Journal of pharmaceutical sciences.

[18]  Mehrdad Hamidi,et al.  Applications of carrier erythrocytes in delivery of biopharmaceuticals. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[19]  S. Mitragotri,et al.  Identification of Peptide Ligands Facilitating Nanoparticle Attachment to Erythrocytes , 2008, Biotechnology progress.

[20]  M. Magnani,et al.  A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus. , 2000, Antiviral research.

[21]  C. Gamazo,et al.  Nanocarriers with gentamicin to treat intracellular pathogens. , 2006, Journal of nanoscience and nanotechnology.

[22]  G. Golomb,et al.  Nanospheres of a bisphosphonate attenuate intimal hyperplasia. , 2006, Journal of Nanoscience and Nanotechnology.

[23]  J. Widness,et al.  RBCs labeled at two biotin densities permit simultaneous and repeated measurements of circulating RBC volume , 2004, Transfusion.

[24]  S. Takeoka,et al.  Selective uptake of surface-modified phospholipid vesicles by bone marrow macrophages in vivo. , 2007, Biomaterials.

[25]  A. Palamara,et al.  Glutathione inhibits HIV replication by acting at late stages of the virus life cycle. , 1996, AIDS research and human retroviruses.

[26]  G. Soma,et al.  Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[27]  C. Min,et al.  IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation , 2007, Bone Marrow Transplantation.

[28]  J. M. Lanao,et al.  Factors associated with the performance of carrier erythrocytes obtained by hypotonic dialysis. , 2004, Blood cells, molecules & diseases.

[29]  H. Neumann,et al.  TREM2-Transduced Myeloid Precursors Mediate Nervous Tissue Debris Clearance and Facilitate Recovery in an Animal Model of Multiple Sclerosis , 2007, PLoS medicine.

[30]  T. Takayama,et al.  Amelioration of murine dextran sulfate sodium‐induced colitis by ex vivo extracellular superoxide dismutase gene transfer , 2006, Inflammatory bowel diseases.

[31]  K. Moelling,et al.  Anti‐tumor activity of mesenchymal stem cells producing IL‐12 in a mouse melanoma model , 2006, Experimental dermatology.

[32]  E. Beutler,et al.  Enzyme Replacement in Gaucher Disease , 2004, PLoS medicine.

[33]  M. van Lookeren Campagne,et al.  Macrophage complement receptors and pathogen clearance , 2007, Cellular microbiology.

[34]  G. Damonte,et al.  Synthesis and targeted delivery of an azidothymidine homodinucleotide conferring protection to macrophages against retroviral infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Gordon,et al.  Recent progress in defining the role of scavenger receptors in lipid transport, atherosclerosis and host defence. , 1998, Current opinion in lipidology.

[36]  D. Werling,et al.  Role of sugars in surface microbe-host interactions and immune reaction modulation. , 2007, Veterinary dermatology.

[37]  M. Magnani,et al.  Efficient inhibition of macrophage TNF‐α production upon targeted delivery of K48R ubiquitin , 1999 .

[38]  Michele De Luca,et al.  Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells , 2006, Nature Medicine.

[39]  R. Khosravi‐Far,et al.  Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo. , 2006, Cancer research.

[40]  Peter E. Nielsen,et al.  PNA hybridizes to complementary oligonucleotides obeying the Watson–Crick hydrogen-bonding rules , 1993, Nature.

[41]  R. Müller,et al.  Effect of solid lipid nanoparticles (SLN) on cytokine production and the viability of murine peritoneal macrophages. , 2000, Journal of microencapsulation.

[42]  M. Magnani,et al.  Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model. , 2002, Antiviral research.

[43]  A. Andriulli,et al.  The polymorphism of multi-drug resistance 1 gene (MDR1) does not influence the pharmacokinetics of dexamethasone loaded into autologous erythrocytes of patients with inflammatory bowel disease. , 2006, European review for medical and pharmacological sciences.

[44]  C. M. Gupta,et al.  Targeted drug delivery to macrophages in parasitic infections. , 2005, Current drug delivery.

[45]  R. Crystal,et al.  SYSTEMIC GLUTATHIONE DEFICIENCY IN SYMPTOM-FREE HIV-SEROPOSITIVE INDIVIDUALS , 1989, The Lancet.

[46]  A. Palamara,et al.  Antiretroviral effect of combined zidovudine and reduced glutathione therapy in murine AIDS. , 1997, AIDS research and human retroviruses.

[47]  E. Read,et al.  Flow cytometric detection of human red cells labeled with a fluorescent membrane label: potential application to in vivo survival studies , 1991, Transfusion.

[48]  L. Naldini,et al.  Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. , 2006, The Journal of clinical investigation.

[49]  J. L. Way,et al.  Erythrocytes as Drug Carriers in Medicine , 1997, Springer US.

[50]  G. Damonte,et al.  Azidothymidine homodinucleotide-loaded erythrocytes and bioreactors for slow delivery of the antiretroviral drug azidothymidine. , 1996, Biochemical and biophysical research communications.

[51]  A. Andriulli,et al.  Erythrocytes-Mediated Delivery of Dexamethasone in Steroid-Dependent IBD Patients—A Pilot Uncontrolled Study , 2005, The American Journal of Gastroenterology.

[52]  Donald L. Swiderski,et al.  Cochlear implants and ex vivo BDNF gene therapy protect spiral ganglion neurons , 2007, Hearing Research.

[53]  M. Magnani,et al.  Erythrocyte-mediated delivery of a new homodinucleotide active against human immunodeficiency virus and herpes simplex virus. , 2001, The Journal of antimicrobial chemotherapy.

[54]  H. Gendelman,et al.  Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. , 2006, Blood.

[55]  D. Hackam,et al.  Toll-like receptor 4 plays a role in macrophage phagocytosis during peritoneal sepsis. , 2007, Journal of pediatric surgery.

[56]  S. Vyas,et al.  Liposome-based drug delivery to alveolar macrophages , 2007, Expert opinion on drug delivery.

[57]  M. Magnani,et al.  Modulated red blood cell survival by membrane protein clustering , 1995, Molecular and Cellular Biochemistry.

[58]  J. Hamuro,et al.  The polarization of T(h)1/T(h)2 balance is dependent on the intracellular thiol redox status of macrophages due to the distinctive cytokine production. , 2002, International immunology.

[59]  María Vallet-Regí,et al.  Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials. , 2006, Journal of the American Chemical Society.

[60]  Y. Tabata,et al.  Transplantation of genetically engineered mesenchymal stem cells improves cardiac function in rats with myocardial infarction: benefit of a novel nonviral vector, cationized dextran. , 2006, Tissue engineering.

[61]  M. Magnani,et al.  Selective inhibition of NF-kB activation and TNF-alpha production in macrophages by red blood cell-mediated delivery of dexamethasone. , 2000, Blood cells, molecules & diseases.

[62]  Gianluca Damonte,et al.  Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. , 2004, Blood cells, molecules & diseases.

[63]  G. Damonte,et al.  Macrophage protection against human immunodeficiency virus or herpes simplex virus by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and acyclovir. , 1998, AIDS research and human retroviruses.

[64]  M. Magnani,et al.  Inhibition of macrophage iNOS by selective targeting of antisense PNA. , 2002, Biochemistry.

[65]  M. Roederer,et al.  Intracellular glutathione levels in T cell subsets decrease in HIV-infected individuals. , 1992, AIDS research and human retroviruses.

[66]  H. Simmonds,et al.  Carrier erythrocyte entrapped adenosine deaminase therapy in adenosine deaminase deficiency. , 2000, Advances in Experimental Medicine and Biology.

[67]  Shugo Nakamura,et al.  IgEb immune complexes activate macrophages through FcγRIV binding , 2007, Nature Immunology.

[68]  H. Gendelman,et al.  Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery , 2006, Journal of leukocyte biology.

[69]  P. Black,et al.  Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. , 2006, Neuro-oncology.

[70]  P. Couvreur,et al.  Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[71]  Mauro Magnani,et al.  Periodic treatment with autologous erythrocytes loaded with dexamethasone 21-phosphate for fistulizing pediatric Crohn's disease: case report. , 2006, Journal of pediatric gastroenterology and nutrition.

[72]  H. Vandenburgh,et al.  Angiogenesis enhances factor IX delivery and persistence from retrievable human bioengineered muscle implants. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[73]  M. Magnani,et al.  Effect of listeriolysin O-loaded erythrocytes on Mycobacterium avium replication within macrophages. , 2004, The Journal of antimicrobial chemotherapy.

[74]  E. Beutler,et al.  Enzyme replacement therapy in Gaucher's disease: preliminary clinical trial of a new enzyme preparation. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[75]  M. Radomski,et al.  Nanoparticles: pharmacological and toxicological significance , 2007, British journal of pharmacology.

[76]  R. Gullapalli,et al.  Macrophage targeted N-(2-hydroxypropyl)methacrylamide conjugates for magnetic resonance imaging. , 2006, Molecular pharmaceutics.

[77]  P. Stieg,et al.  Neural stem cells may be uniquely suited for combined gene therapy and cell replacement: Evidence from engraftment of Neurotrophin-3-expressing stem cells in hypoxic–ischemic brain injury , 2006, Experimental Neurology.

[78]  M. Laguerre,et al.  Acetaldehyde dehydrogenase-loaded erythrocytes as bioreactors for the removal of blood acetaldehyde. , 1989, Alcoholism, clinical and experimental research.

[79]  A. Palamara,et al.  Glutathione inhibits replication and expression of viral proteins in cultured cells infected with Sendai virus. , 1992, Biochemical and biophysical research communications.

[80]  Zhong-gao Gao,et al.  Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. , 2007, Journal of the National Cancer Institute.

[81]  G. Damonte,et al.  Red Blood Cells as a Delivery System for AZT , 1995 .

[82]  V. Rudloff,et al.  Senescent cell antigen is immunologically related to band 3. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[83]  W. Dröge,et al.  Modulation of transcription factor NFχB activity by intracellular glutathione levels and by variations of the extracellular cysteine supply , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[84]  C. de Chastellier,et al.  Phagocytic processing of the macrophage endoparasite, Mycobacterium avium, in comparison to phagosomes which contain Bacillus subtilis or latex beads. , 1995, European journal of cell biology.

[85]  Vladimir R Muzykantov,et al.  Blood Clearance and Activity of Erythrocyte-Coupled Fibrinolytics , 2005, Journal of Pharmacology and Experimental Therapeutics.

[86]  M. Migita,et al.  Ex vivo cell-mediated gene therapy for metachromatic leukodystrophy using neurospheres , 2006, Brain Research.

[87]  M. Magnani,et al.  Erythrocyte-based drug delivery , 2005, Expert opinion on drug delivery.

[88]  N. Jain,et al.  Folate Conjugated Doxorubicin-Loaded Membrane Vesicles for Improved Cancer Therapy , 2003, Drug delivery.

[89]  M. Magnani,et al.  Long-term Treatment With Autologous Red Blood Cells Loaded With Dexamethasone 21–Phosphate in Pediatric Patients Affected by Steroid-dependent Crohn Disease , 2007, Journal of pediatric gastroenterology and nutrition.

[90]  J. Gray,et al.  Intravascular administration of tumor tropic neural progenitor cells permits targeted delivery of interferon-beta and restricts tumor growth in a murine model of disseminated neuroblastoma. , 2007, Journal of pediatric surgery.

[91]  M. Pinilla,et al.  Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation in vivo survival rate in circulation, organ distribution and ethanol degradation. , 2001, Life sciences.

[92]  L. Yahia,et al.  Therapeutic potential of nanoparticulate systems for macrophage targeting. , 2005, Biomaterials.

[93]  M. Magnani,et al.  Drug Delivery through Phagocytosis of Red Blood Cells , 2004, Transfusion Medicine and Hemotherapy.

[94]  Mehrdad Hamidi,et al.  Carrier Erythrocytes: An Overview , 2003, Drug delivery.

[95]  T. Philip,et al.  Tolerance Evaluation of L-asparaginase loaded in red blood cells , 1996, European Journal of Clinical Pharmacology.

[96]  E. Silberstein,et al.  The in vivo survival of human red cells with low oxygen affinity prepared by the osmotic pulse method of inositol hexaphosphate incorporation , 1990, Transfusion.

[97]  C. Gamazo,et al.  Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin. , 2006, The Journal of antimicrobial chemotherapy.

[98]  A. De Flora,et al.  Heterodimer-loaded erythrocytes as bioreactors for slow delivery of the antiviral drug azidothymidine and the antimycobacterial drug ethambutol. , 1999, AIDS research and human retroviruses.

[99]  W. Lubitz,et al.  Bacterial ghosts as adjuvant particles , 2007, Expert review of vaccines.

[100]  A. Palamara,et al.  Evidence for antiviral activity of glutathione: in vitro inhibition of herpes simplex virus type 1 replication. , 1995, Antiviral research.

[101]  M. Magnani,et al.  Encapsulation, metabolism and release of 2-fluoro-ara-AMP from human erythrocytes. , 1996, Biochimica et biophysica acta.

[102]  C. Perno,et al.  Inhibition of HIV-1 Replication in Macrophages by Red Blood Cell-Mediated Delivery of a Heterodinucleotide of Azidothymidine and 9-(R)-2-(Phosphono Methoxypropyl)adenine , 2001, Antiviral chemistry & chemotherapy.

[103]  B. Gander,et al.  In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[104]  T. Ohmori,et al.  Efficient expression of a transgene in platelets using simian immunodeficiency virus‐based vector harboring glycoprotein Ibα promoter: in vivo model for platelet‐targeting gene therapy , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[105]  Anna A Shvedova,et al.  Nanomedicine and nanotoxicology: two sides of the same coin. , 2005, Nanomedicine : nanotechnology, biology, and medicine.

[106]  J. M. Lanao,et al.  Drug, enzyme and peptide delivery using erythrocytes as carriers. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[107]  Sergey S Shevkoplyas,et al.  A high‐resolution, double‐labeling method for the study of in vivo red blood cell aging , 2006, Transfusion.

[108]  B. Nordén,et al.  Phospholipid membrane permeability of peptide nucleic acid , 1995, FEBS letters.

[109]  V. Muzykantov,et al.  Immunotargeting of erythrocyte-bound streptokinase provides local lysis of a fibrin clot. , 1986, Biochimica et biophysica acta.